ICU Medical, Inc. ICUI
At closeNov 4, 2026, 4:17 AM EST
Pre-market · Nov 4, 4:17 AM ET
- YTD
- +13.43%
- 1 year
- +31.72%
- Market cap
- 4.05B
- Revenue (ttm)
- 2.16B
- Profit margin
- 1.39%
- EPS (ttm)
- 1.19
- Shares out
- 25.01M
- P/E ratio
- 135.99
- Forward P/E
- 16.78
- YTD return
- +13.43%
- 1-year return
- +31.72%
- Volume
- 297.80K
- Avg volume
- 255.62K
- Open
- 163.00
- Previous close
- 162.38
- Day's range
- 160.40 – 166.48
- 52-week range
- 113.37 – 192.85
- Beta
- 0.88
- Analysts
- Buy
- Price target
- 193.38 (+19.5%)
- Earnings date
- Nov 5, 2026
2Y -10.17 (-5.91%)
Key statistics
- Enterprise value
- 5.05B
- PEG ratio
- 0.08
- Price / sales
- 1.87
- Price / book
- 1.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.50%
- Free cash flow
- 163.56M
- Total cash
- 302.64M
- Total debt
- 1.29B
- Return on equity
- 1.41%
- Short % of float
- 8.20%
- 50-day average
- 163.81
- 200-day average
- 148.63
Analyst view
Consensus: buy
- Target (low)
- 178.00
- Target (mean)
- 193.38
- Target (high)
- 210.00
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 2.15.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 2.14 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 1.91 | 2.37 | +0.46 | +24.08% |
| May 7, 2026 | Mar 31, 2026 | 1.78 | 1.97 | +0.19 | +10.67% |
| Feb 19, 2026 | Dec 31, 2025 | 1.68 | 1.91 | +0.23 | +13.69% |
| Nov 6, 2025 | Sep 30, 2025 | 1.43 | 2.03 | +0.60 | +41.96% |
| Aug 7, 2025 | Jun 30, 2025 | 1.44 | 2.10 | +0.66 | +45.83% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 7, 2026 | BTIG | main | Buy | Buy |
| Aug 7, 2026 | Needham | main | Buy | Buy |
| Jul 21, 2026 | Keybanc | main | Overweight | Overweight |
| Jun 15, 2026 | BTIG | init | — | Buy |
| May 27, 2026 | Needham | up | Hold | Buy |
About ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- icumed.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ICUI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABBEY DONALD M | Director | Conversion of Exercise of derivative security | May 12, 2026 | 6,004 |
| BONNELL BRIAN MICHAEL | Chief Financial Officer | Sale | Aug 31, 2026 | 56,062 |
| FINNEY ELISHA W | Director | Sale | Aug 10, 2026 | 4,871 |
| GREENBERG DAVID C | Director | Conversion of Exercise of derivative security | May 12, 2026 | 9,214 |
| HERNANDEZ LAURIE | Director | Conversion of Exercise of derivative security | May 12, 2026 | 4,862 |
| HOFFMEISTER DAVID F | Director | Conversion of Exercise of derivative security | May 12, 2026 | 6,004 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.02% | 3,753,409 | 607.41M | Jun 29, 2026 |
| Jupiter Topco LLC | 11.13% | 2,781,620 | 450.15M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.88% | 1,470,583 | 237.98M | Jun 29, 2026 |
| Fuller & Thaler Asset Management Inc. | 5.19% | 1,298,127 | 210.08M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.49% | 1,123,237 | 181.77M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 4.21% | 1,053,476 | 170.48M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.96% | 1,489,253 | 241.01M | Sep 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 4.92% | 1,230,753 | 199.17M | Jun 29, 2026 |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.22% | 1,054,324 | 170.62M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 791,929 | 128.16M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 641,126 | 103.75M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 573,522 | 92.81M | Jun 29, 2026 |
